Nanotherapeutics

Your Biopharmaceutical Development and Manufacturing Partner

Nanotherapeutics Gets FDA Orphan-Drug Status for NanoDTPA™ Capsules to Treat Radiation Exposure

PRWeb Wire - June 2011

FDA approves orphan-drug designation to Nanotherapeutics' new oral capsule under development for treatment of radiation exposure. NanoDTPA™ capsule is one of several products the company is developing for chemical, biological, radiological and nuclear (CBRN) medical countermeasures. 

Full Article

Copyright 2015 NANOTHERAPEUTICS, INC.  All rights reserved.